1-20 of 35
Gabriel N. Mannis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Significance of Low Copy Number FLT3 and NPM1 mrd As Detected By Ultra-Sensitive Next Generation Sequencing

Morgan L Shannon, Tian Y Zhang, Lori Muffly, Gabriel N Mannis
Journal: Blood
Blood (2024) 144 (Supplement 1): 4330.
https://doi.org/10.1182/blood-2024-204291
Published: 2024
Journal Articles

Prognostic Significance of CD123 Expression in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Bruce C Tiu, Christina J Su, Emma C St. Martin, Jean S Oak, Tian Y Zhang, Gabriel N Mannis
Journal: Blood
Blood (2024) 144 (Supplement 1): 6104.
https://doi.org/10.1182/blood-2024-205837
Published: 2024
Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Gabriel N Mannis, Ahmed Aribi, Neil Dunavin, Hetty E. Carraway, Jennifer N. Saultz, Gail J. Roboz, Brian A. Jonas, Yazan F Madanat, Guillermo Garcia-Manero, Deepa Jeyakumar, Daniel A Pollyea, Olatoyosi Odenike, William Blum, Gary J. Schiller, Yasuhiro Tabata, Donna Valencia, Tao Huang, Wen Hong Lin, Hong Xiang, Charlene Liao, Courtney D. DiNardo
Journal: Blood
Blood (2024) 144 (Supplement 1): 1008.
https://doi.org/10.1182/blood-2024-206538
Published: 2024
Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland
Journal: Blood
Blood (2024) 144 (Supplement 1): 5998.
https://doi.org/10.1182/blood-2024-204046
Published: 2024
Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Ibrahim Aldoss, Ghayas C. Issa, James S. Blachly, Michael J. Thirman, Gabriel N Mannis, Martha L. Arellano, John F. DiPersio, Elie Traer, C. Michel Zwaan, Neerav Shukla, Branko Cuglievan, Carolyn S. Grove, Matthew Greenwood, Christine M. McMahon, Alexander E. Perl, Richard M. Stone, Cristina Papayannidis, David S. Dickens, Maël Heiblig, Andrius Žučenka, Pau Montesinos, Ioannis Mantzaris, Tibor Kovacsovics, Paul J. Shami, Li Yu, Rebecca G. Bagley, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2024) 144 (Supplement 1): 211.
https://doi.org/10.1182/blood-2024-194384
Published: 2024
Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Daniel J. DeAngelo, Andre C. Schuh, Brian A. Jonas, Pamela S. Becker, Anjali S. Advani, Geoffrey L. Uy, Janusz Krawczyk, Harry P. Erba, Gabriel N Mannis, Chun Yew Fong, Florian Kuchenbauer, Mary-Elizabeth M. Percival, Jane L. Liesveld, William Blum, Brenda W Cooper, Alice Mims, Francesco Lanza, Jeroen J.W.M. Janssen, Juan Miguel Bergua Burgues, Tibor Kovacsovics, Norbert Vey, Martina V. Hemmer, Gaetano Bonifacio, Edwin Rock, Pau Montesinos
Journal: Blood
Blood (2024) 144 (Supplement 1): 733.
https://doi.org/10.1182/blood-2024-209097
Published: 2024
Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Pau Montesinos, Brian A. Jonas, Martha L. Arellano, Uma Borate, Justin M. Watts, Paul B. Koller, Chul Won Jung, Sang Kyun Sohn, Amir T. Fathi, Pankit Vachhani, Nikolai A. Podoltsev, Olga Salamero, Sung-Soo Yoon, Jeong-Ok Lee, Gabriel N Mannis, Shuhying Tan, Sudipto Mukherjee, Harry Erba, Ho-Jin Shin, Uwe Platzbecker, Mar Tormo, Eric Tam, Leanne Berkahn, Teresa Bernal, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, Nawazish Khan, Vivian Costa Victory, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2024) 144 (Supplement 1): 4255.
https://doi.org/10.1182/blood-2024-200397
Published: 2024
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel N. Mannis, Alexander Perl, David S. Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J. Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G. Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-5.
https://doi.org/10.1182/blood-2023-192042
Published: 2023
Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 3312–3314.
https://doi.org/10.1182/blood-2022-159680
Published: 2022
Journal Articles

Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis

Vishesh Khanna, Tali Azenkot, Selina (Qiuying) Liu, Jason Gilbert, Edna Cheung, Kimberly Lau, Daniel A. Pollyea, Elie Traer, Brian A. Jonas, Tian Y. Zhang, Gabriel N. Mannis
Journal: Blood
Blood (2022) 140 (Supplement 1): 3294–3296.
https://doi.org/10.1182/blood-2022-166803
Published: 2022
Journal Articles

Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia

Daria Gaut, Caspian Oliai, Jonathan Boiarsky, Shiliang Zhang, Tali Azenkot, Vanessa E. Kennedy, Vishesh Khanna, Karla Olmedo Gutierrez, Navika D. Shukla, Benjamin Moskoff, Anand Ashwin Patel, Deepa Jeyakumar, Gabriel N. Mannis, Aaron C. Logan, Brian A. Jonas, Gary J. Schiller
Journal: Blood
Blood (2022) 140 (Supplement 1): 3374–3376.
https://doi.org/10.1182/blood-2022-156842
Published: 2022
Journal Articles

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 1268.
https://doi.org/10.1182/blood-2021-148054
Published: 2021
Journal Articles

A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

Gabriel N. Mannis, Elizabeth A. Griffiths, Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Casey L. O'Connell, Jacqueline Dillingham, Prieya Wason, Lixia Zhu, Danna Chan, Harold N. Keer, Aram Oganesian, Kim-Hien Dao, Courtney D. DiNardo
Journal: Blood
Blood (2021) 138 (Supplement 1): 1245.
https://doi.org/10.1182/blood-2021-146264
Published: 2021
Journal Articles

Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation

Emily C. Liang, Connie Chen, Rong Lu, Gabriel N. Mannis, Lori Muffly
Journal: Blood
Blood (2021) 138 (Supplement 1): 1306.
https://doi.org/10.1182/blood-2021-149805
Published: 2021
Journal Articles

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Irena Tan, Matthew Schwede, Paul Phan, Raymond Yin, Tian Y Zhang, Gabriel N. Mannis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1216.
https://doi.org/10.1182/blood-2021-147886
Published: 2021
Journal Articles

Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML

Gavin Hui, MD, Abdullah Ladha, MD, Edna Cheung, PharmD, Caroline Berube, MD, Steven Coutre, MD, Jason Gotlib, MD MS, Michaela Liedtke, MD, Tian Y Zhang, MD PhD, Lori S. Muffly, MD MS, Gabriel N. Mannis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-142691
Published: 2020
Journal Articles

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-136868
Published: 2020
Journal Articles

The Value of an Embedded Outpatient Palliative Care Program in Malignant Hematology: Concurrent Care and the Impact on Health Care Utilization

Mazie Tsang, MD, Kelly L. Schoenbeck, MD, Kim Berry, MBA, Eve Cohen, RN, Kara Bischoff, MD, Nancy Shepard Lopez, NP, Gabriel N. Mannis, MD, Michael Rabow, MD FAAHPM
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-142305
Published: 2020
Journal Articles

Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

Vanessa E Kennedy, MD, Gavin Hui, MD, Daria Gaut, MD, Varun Mittal, MD, Caspian Oliai, MD, Lori S. Muffly, MD MS, Aaron C. Logan, MDPhDMPhil, Gabriel N. Mannis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-143002
Published: 2020
Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Clinical Trials & Observations
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Journal: Blood
Blood (2020) 135 (7): 463–471.
https://doi.org/10.1182/blood.2019002140
Published: 2020
Includes: Supplemental data